Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | DRD1 | P21728 | 5/20 | 0.46 |
| ▸ | DRD5 | P21918 | 5/20 | 0.46 |
| ▸ | DRD3 | P35462 | 5/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13005003 | 0.88 | AKT1 (0.48) | DRD2DRD1DRD5DRD3HTR2A | |
| SCHEMBL13720817 | 0.82 | CA2 (0.46) | DRD2HTR2AHTR2CCHRNA7CA2 | |
| SCHEMBL13005016 | 0.79 | DRD2 (0.51) | DRD2DRD1DRD5DRD3HTR2A | |
| SCHEMBL5317315 | 0.77 | HTR2A (0.64) | DRD2DRD1DRD5DRD3HTR2A | |
| SCHEMBL31254037 | 0.77 | ALDH1A1 (0.49) | OPRM1CHRNA7CA2CA5A | |
| SCHEMBL4974003 | 0.77 | ALDH1A1 (0.49) | OPRM1CHRNA7CA2CA5A | |
| Formaldehyde SCHEMBL27953583 | 0.73 | ALDH1A1 (0.49) | CA2CA5A | |
| SCHEMBL9284097 | 0.73 | ESR2 (0.44) | OPRM1OPRK1CA2CA5AOPRD1 | |
| SCHEMBL13698990 | 0.73 | HTR2A (0.43) | DRD2HTR2AHTR2CSIGMAR1 | |
| SCHEMBL12470516 | 0.73 | KDM4E (0.40) | CA2CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | LIGAND PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | HRH3, HRH4, HRH2 | DRD2 807/4885DRD1 1080/4885DRD5 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.